Alliance Pharma plc (APH) Earns Buy Rating from Numis Securities Ltd

Numis Securities Ltd restated their buy rating on shares of Alliance Pharma plc (LON:APH) in a research note issued to investors on Wednesday morning. They currently have a GBX 60 ($0.77) target price on the stock.

Separately, FinnCap reaffirmed a buy rating and set a GBX 58 ($0.75) price target on shares of Alliance Pharma plc in a research report on Thursday, August 24th.

Alliance Pharma plc (LON:APH) opened at 52.75 on Wednesday. Alliance Pharma plc has a 12-month low of GBX 41.33 and a 12-month high of GBX 57.56. The company’s market capitalization is GBX 249.36 million. The firm’s 50-day moving average price is GBX 52.51 and its 200 day moving average price is GBX 50.61.

WARNING: “Alliance Pharma plc (APH) Earns Buy Rating from Numis Securities Ltd” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/16/alliance-pharma-plc-aph-earns-buy-rating-from-numis-securities-ltd.html.

Alliance Pharma plc Company Profile

Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international.

Receive News & Ratings for Alliance Pharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliance Pharma plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply